Global pharmaceutical company Allergan has manufactured the 100 millionth vial of botulinum toxin type A Botox, which the company has said is a ‘significant milestone in the history of the brand’.
Global pharmaceutical company Allergan is launching a website to support healthcare professionals working within medical aesthetics called Allergan Spark.
The Food and Drug Administration (FDA) has approved Jeuveau, a botulinum toxin type A, for the temporary improvement in the appearance of moderate to severe glabellar lines.
A hands-on workshop focusing on lower face and neck treatments using botulinum toxin will take place on February 27.
High street retailer Superdrug, which started offering a botulinum toxin and dermal filler service last year, has said that it will introduce tougher mental health checks for patients as a result of concerns voiced by the NHS.
IQ Resources, a sister company to IQ Verify, a UKAS accredited certification body has launched a new eLearning package titled the Botulinum Toxin and Dermal Filler Level 7 eLearning.
Independent accreditation body Save Face has published its consumer complaints audit report for 2017-2018.
Global pharmaceutical company Allergan has announced plans to build a USD $14.7 million centre to promote medical aesthetics innovations in Chengdu, China, which will train 3,000 practitioners per year.
Aesthetic training provider Cosmetic Courses has announced that it will be launching its existing courses in Belfast, Northern Ireland, from November.
A clinical study conducted by global pharmaceutical company Allergan suggests that higher doses of Botox Cosmetic (onabotulinumtoxinA) to treat moderate to severe glabella lines produces greater duration of treatment effect.